CD40LG and COVID-19: In the current study where all participants were enrolled more than 2 months after vaccination, 5.5% of the enrolled participants were IgM seropositive at the time of enrollment indicating acute SARS-CoV-2 infection before immunity was mounted due to either underlying factors or COVID-19 vaccine breakthrough infections.